ScoreComparison
Why is Beam Therapeutics, Inc. ?
1
The company has declared Negative results for the last 3 consecutive quarters
- NET SALES(Q) At USD 9.7 MM has Fallen at -32.03%
- ROCE(HY) Lowest at -47.19%
- RAW MATERIAL COST(Y) Grown by 31.27% (YoY)
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -0.25%, its profits have fallen by -215.5%
3
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -1.01% over the previous quarter and currently hold 8.03% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -0.25% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Beam Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Beam Therapeutics, Inc.
-3.71%
-0.02
77.14%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
124.23%
EBIT Growth (5y)
-214.18%
EBIT to Interest (avg)
-309.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
0.21
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.69
EV to EBIT
-3.29
EV to EBITDA
-3.45
EV to Capital Employed
-15.93
EV to Sales
27.54
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-43.71%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
NET PROFIT(HY)
Higher at USD -223.73 MM
-16What is not working for the Company
NET SALES(Q)
At USD 9.7 MM has Fallen at -32.03%
ROCE(HY)
Lowest at -47.19%
RAW MATERIAL COST(Y)
Grown by 31.27% (YoY
OPERATING PROFIT(Q)
Lowest at USD -121.25 MM
PRE-TAX PROFIT(Q)
Lowest at USD -115.91 MM
NET PROFIT(Q)
Lowest at USD -115.91 MM
Here's what is working for Beam Therapeutics, Inc.
Depreciation
Highest at USD 5.56 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Beam Therapeutics, Inc.
Net Sales
At USD 9.7 MM has Fallen at -32.03%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Operating Profit
Lowest at USD -121.25 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Pre-Tax Profit
Lowest at USD -115.91 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -115.91 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Raw Material Cost
Grown by 31.27% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
